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Severe acute respiratory syndrome (SARS) is a highly contagious and sometimes a lethal disease, which spread over five continents in
2002–2003. Laboratory analysis showed that the etiologic agent for SARS is a new type of coronavirus. Currently, there is no specific
treatment for this disease. RNA interference (RNAi) is a recently discovered antiviral mechanism in plant and animal cells that induces a
specific degradation of double-stranded RNA. Here, we provide evidences that RNAi targeting at coronavirus RNA-dependent RNA
polymerase (RDRP) using short hairpin RNA (shRNA) expression plasmids can specifically inhibit expression of extraneous coronavirus
RDRP in 293 and HeLa cells. Moreover, this construct significantly reduced the plaque formation of SARS coronaviruses in Vero-E6 cells.
The data may suggest a new approach for treatment of SARS patients.
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Severe acute respiratory syndrome (SARS) is a highly
contagious disease. An outbreak in 2002–2003 affected
more than 8000 patients in over 30 countries across five
continents. In some areas, the mortality reached as high as
10% of the infected patients (WHO). Viruses isolated
from SARS patients have been confirmed to be a new
type of coronavirus that is responsible for the outbreak
(Enserink and Normile, 2003; Guan et al., 2003; Lai,
2003; Yan et al., 2003). Coronaviruses are large envel-
oped, positive-stranded RNA viruses that cause diseases in0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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They have the largest genomes in all RNA viruses and
replicate by a unique mechanism, which results in high
frequency of recombination. Similar to influenza virus,
coronaviruses are highly mutable and therefore the infec-
tion is extremely difficult to treat (Knipe and Howley,
2001).
RNA interference (RNAi) is a native process in which
the introduction of a short double-stranded RNA into
cells results in posttranscriptional silencing of the targeted
genes. This gene silencing was found to be a gene-
specific mechanism for regulation of complex biological
functions. RNAi has been successfully used in C. ele-
gans, fungi, Drosophila, and mammalian cells to study
gene functions (Elbashir et al., 2001a, 2001b; Fire et al.,
1998; Kadotani et al., 2003). Recently, several reports
have demonstrated the use of RNAi for attenuation of
viral infection and replication in animal cells, suggesting
that RNAi might become a therapeutic approach in the
future for treating viral diseases (Gitlin et al., 2002;
Jacque et al., 2002; Jia and Sun, 2003; Kapadia et al.,
A. Lu et al. / Virology 32003; Novina et al., 2002; Qin et al., 2003; Randall et
al., 2003).
The goal of this study is to test the inhibitory effect of
RNAi on the expression of RNA-dependent RNA polymer-
ase (RDRP) of SARS coronavirus, and the potential of
RNAi to attenuate the plaque formation of SARS corona-
virus in infected animal cells. Here, we provide the evidence
that RNAi targeting at coronavirus RDRP using short
hairpin RNA (shRNA) expression plasmids can specifically
inhibit expression of extraneous coronavirus RDRP in 293
and HeLa cells. Moreover, this construct significantly re-
duced the plaque formation of SARS coronaviruses in Vero-
E6 cells. The results may suggest a new approach for
treatment of SARS.Results
Design of specific shRNA expression plasmids targeting at
coronavirus RDRP
Coronavirus isolated from SARS patients has a large
genomic RNA (approximately 30 kb). When the virus
replicates, errors are generated with a high frequency,
making the virus particularly difficult to target. We therefore
chose the target genes in the viral genome that are conserved
in different strains of coronavirus. One of the candidates is
RDRP (GeneBank AY 268070). This gene has 645 bp and
codes a 215-amino-acid peptide. BLAST analysis shows
that there is almost no mismatch in this region of corona-
viruses. This sequence has no homology with any known
human genes.
Among 25 candidate fragments, five panels of DNA
sequences (Table 1) were synthesized and inserted into
pSilence1.0-U6. With the U6 pol III promoter, the plas-
mids express a 55-nt RNA stem-loop. After transfecton,
about 40–90% of RDRP gene expression was inhibited,
depending on the sequence of the shRNA inserts, based on
RT-PCR analysis in both HeLa and 293 cells transfected
with RDRP (data not shown). Therefore, we selected the
most potent plasmid inserted with sequence A (plasmid-A,
see Table 1) for subsequent experiments. A mutated
version of the inserted sequence-A with 6-nt mismatch
was also synthesized as a specific negative control (plas-
mid-A*, Table 1).Table 1
The sequences of shRNA inserts for pSilence 1.0 U6
Sequence Targeting
A 5V-ATCTTAGG
A* 5V-ATGTTAGC
(mutated bases
B 5V-TATGACTAT
C 5V-TGTCAACC
D 5V-TGTCTGATA
E 5V-AGGACATGshRNA reduced the expression of SARS RDRP mRNA in 293
and HeLa cells
As shown in Fig. 1A, based on the RT-PCR analysis, the
expression of extraneous RDRP gene was observed peaking
at 48 h after the transfection. When 293 cells were co-
transfected with pIRES-2-EGFP/RDRP plasmid along with
shRNA expression plasmid-A, the RDRP mRNA was re-
duced to 25% of that of the control cells measured at 24
h after the transfection, and the RDRP mRNA can no longer
be detected 48 h after the transfection (Fig. 1B, lane 4). No
inhibitory effect was observed in the cells co-transfected
with pIRES-2-EGFP/RDRP along with plasmid-A* (Fig.
1B, lane 5). The inhibitive effect on RDRP by plasmid-A
was also observed in HeLa cells (data not shown).
shRNA reduced the production of SARS RDRP proteins
To confirm the effect of shRNA on RDRP expression, we
performed Western blot analysis. Because anti-RDRP anti-
body is not commercially available, antibody against HA
tag was used to detect the production of RDRP proteins, in
which an HA epitope tag had been introduced at the N-
terminus. The results showed that the production of RDRP
proteins was reduced by more than 90% in cells co-trans-
fected with plasmid-A (Fig. 2B, lane 4). The specificity of
the RNAi was again demonstrated in that no inhibitory
effect on RDRP protein expression was observed in the cells
co-transfected with plasmid-A* (Fig. 2, lane 5).
The reduction of RDRP protein in the target cells was
also analyzed by immunofluorescence. Again, RDRP pro-
duction was significantly reduced by plasmid-A (Fig. 3D),
but not by plasmid-A* (Fig. 3E). In addition, we noticed an
interesting phenomenon: RDRP proteins appeared to be
located in the cytoplasm, but somehow accumulated in the
nucleus of the cells 48 h after the transfection (Fig. 3). The
significance of this finding is as yet unknown.
Inhibition of plaque formation of SARS coronavirus in
Vero-E6 cells
To test whether shRNA expression plasmid could indeed
attenuate SARS coronavirus infection, the plaque formation
was analyzed in Vero-E6 cells. Plaques are routinely
counted at 48 h after coronavirus infection. No difference
24 (2004) 84–89 85ATTGCCTACGCttcaagagaGCGTAGGCAATCCTAAGATTTTTTT3V 24
ATTGCCTAGGCttcaagagaGCCTAGGCAATGCTAACATTTTTTT-3V 24
underlined)
GTCATATTCAttcaagagaTGAATATGACATAGTCATATTTTTT-3V 72
GCTTCAATGTGttcaagagaCACATTGAAGCGGTTGACATTTTTT-3V 137
GAGATCTTTAttcaagagaTAAAGATCTCTATCAGACATTTTTT-3V 178
ACCTACCGTAGttcaagagaCTACGGTAGGTCATGTCCTTTTTTT-3V 394
Fig. 1. Silencing of the extraneous SARS RDRP gene in 293 cells analyzed by RT-PCR. (A) 293 cells were transfected with pIRES-2-EGFP (lane 1), pIRES-
2-EGFP plus pSilence1.0-U6 (lane 2), pIRES-2-EGFP/RDRP (lane 3), pIRES-2-EGFP/RDRP plus shRNA expression plasmid-A (lane 4), and pIRES-2-
EGFP/RDRP plus specific mutant plasmid-A* (lane 5), respectively, and measured at 24, 48, and 72 h after transfection. (B) The intensity of RT-PCR bands
was quantified by Kodak Image Station. These experiments were repeated three times.
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cells and cells transfected with either pSilence 1.0-U6 or
plasmid-A*. However, the plaque number was significantly
reduced in the cells transfected with shRNA expression
plasmid-A, indicating that this shRNA expression plasmid
could effectively inhibit plaque formation of SARS corona-
virus in Vero-E6 cells (Fig. 4).Fig. 2. Inhibition of the expression of extraneous SARS RDRP proteins in 293 cel
pSilence1.0-U6 (lane 2), pCMV-HA-RDRP (lane 3), pCMV-HA-RDRP plus sh
mutant plasmid-A* (lane 5), respectively, and measured at 24, 48, and 72 h after
Kodak Image Station. These experiments were repeated three times.Discussion
The etiologic agent for SARS has been proven to be
coronavirus. Because RDRP is the key enzyme for corona-
virus replication and its sequences are very conserved in
different isolates of coronaviruses, it might be a good target
to inhibit the replication of coronavirus in SARS patients.ls. (A) 293 cells were transfected with pCMV- HA (lane 1), pCMV-HA plus
RNA expression plasmid-A (lane 4), and pCMV-HA-RDRP plus specific
transfection. (B) The intensity of Western blotting bands was quantified by
Fig. 3. Inhibition of the production of SARS RDRP proteins in 293 cells analyzed by immunofluorescence. 293 cells were transfected with pCMV-HA (A),
pCMV-HA plus pSilence1.0-U6 (B), pCMV-HA-RDRP (C), pCMV-HA-RDRP plus shRNA expression plasmid-A (D), and pCMV-HA-RDRP plus specific
mutant plasmid-A* (E), respectively, and stained at 24, 48, and 72 h after transfection.
Fig. 4. Inhibition of plaque formation of SARS coronavirus on Vero-E6
cells. (A) Plaque formation in Vero-E6 cells was visualized by staining with
crystal violet. Vero-E6 cells were infected with 32 pfu of SARS coronavirus
after having been transfected with: (a) no treatment; (b) pSilence1.0-U6; (c)
shRNA expression plasmid-A; and (d) the mutant plasmid-A*, respectively.
(B) The numbers of plaque formation were counted 48 h after virus infection.
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and 293 cells were transfected with SARS coronavirus
RDRP, and the effect of RNAi on inhibition of RDRP of
coronavirus was tested. Our data showed that the shRNA
expression plasmid for RDRP, plasmid-A, reduced the
expression of RDRP in both mRNA and protein levels by
more than 90% in both 293 and HeLa cells.
Inhibition of RDRP by the shRNA expression plasmid-A
in the RDRP-transfected cells may not necessary to be
warranted in cells infected with SARS coronavirus. We
therefore tested the inhibition of coronavirus infection by
the shRNA expression plasmid-A in Vero-E6 cells infected
with the virus. The data clearly demonstrated that the
plaque formation of SARS coronavirus was significantly
inhibited by this plasmid-A, suggesting the shRNA expres-
sion plasmids might indeed inhibit the replication of SARS
coronavirus.
Numbers of studies have shown that RNAi is an impor-
tant mechanism for host defense in plant as well as in
mammalian cells (Baulcombe, 2002; Ge et al., 2003; Ran-
A. Lu et al. / Virology 324 (2004) 84–8988dall et al., 2003; Xia et al., 2002). It has been reported that
short interfering RNA (siRNA) worked as antiviral tools in
cell culture for HIV, HCV, and herpesvirus (Jia and Sun,
2003; Kapadia et al., 2003; Novina et al., 2002; Qin et al.,
2003). There have also been reports in regard to treat
diseases by siRNA in mice (McCaffrey et al., 2002; Song
et al., 2003). Delivery of RNAi in those animal studies all
depends on a high-pressure injection via mouse-tail vein,
which is not practical for humans. Delivery method is
therefore a limiting factor for application of RNAi in
treating human diseases.
Combined the information together with our study, we
therefore proposed that inhibition of RDRP by the shRNA
expression plasmid, plasmid-A, might be an anti-coronavi-
rus agent for treating of SRAS patients. In fact, Dr. He et al.
most recently reported that siRNA targeting at RDRP could
knock down SARS viral genes in FRhk-4 cells (He et al.,
2003). Our data not only confirmed their findings, but also
provide the new RNAi tool, the shRNA expression plas-
mids. Considering that the shRNA expression plasmids can
be easily incorporated into viral vectors for in vivo delivery,
this study may suggest a new method to treat SARS patients
in the future.Methods
Cell culture
Vero-E6, 293, and HeLa cells were routinely cultured in
Dulbecco’s modified Eagle’s medium supplemented with
10% of fetal bovine serum.
Plasmid construction
The RDRP gene of coronavirus was synthesized by
GeneArt Company (GeneArt GmbH, Rosenberg, Germany)
based on the RDRP sequence (GeneBank accession number
AY 268070). The synthetic RDRP gene was cloned into
KpnI/SacI sites of pCRScript Amp (Stratagene). The RDRP
gene was PCR amplified using primers: forward:
5VGCGGAATTCATGCAGGACGCTGTAGCTTC and re-
verse: 5VGCGGGATCCTCAT AGGTTAT TTTCAGTGTC.
The PCR product was digested with EcoRI/BamHI and
cloned into mammalian expression vector pIRES-2-EGFP
or pCMV-HA that introduced an HA epitope tag at the N-
terminus of the proteins. All the inserted sequences were
verified by DNA sequencing.
shRNA inserts
The shRNA inserts (Table 1) were designed by web-
based tools (www.ambion.com/techlib/misc/sirna_finder.
html). We designed 25 different pairs of shRNA inserts
based on the following criteria: (1) the 19 nucleotides are
immediately downstream of an AA di-nucleotide in thecoding region of the target gene. (2) The sequence should
not contain a repeats of more than four As or Ts. A total five
pairs of shRNA inserts were synthesized and inserted into
linearized pSilence1.0-U6 (Ambion) according the manu-
facturer’s manual.
Transfection
HeLa and 293 cells were seeded in a 6 well plate at
3  105/well the day before transfection. One micro-
gram of RDRP expression plasmids, pIRES-2-EGFP/
RDRP or pCMV-HA-RDRP, was co-transfected along
with 1 Ag of shRNA expression plasmid-A (the best of
shRNAs tested) in Lipofectamine 2000 (GibcoBRL),
respectively. The plasmids without inserts or the mutant
shRNA expression construct, plasmid-A*, was used as
negative controls.
RT-PCR
Total RNA from each well of cells was isolated using
RNAeasy kit (Qiagen). RT-PCR was carried out with M-
MLV kit (GibcoBRL) at 42 jC for 1 h. The reverse
transcriptase was then inactivated by heating at 70 jC
for 15 min. PCR was performed with 2 Al of cDNA and
specific primers: RDRP: forward: 5VGCGGAATTCATG
CAGGACGCTGTAGCTTC3V and reverse: 5VGCGGGATC
CTCATAGGTTATTTTCAGTGTC 3V; G3PDH: forward:
5V GAAGGTGAAGGTCGGAGT and reverse: 5V GAAGA
TGTGATGGGATTTC. PCRwas carried out at 95 jC 2min,
then 95 jC 30 s, 55 jC 1min, 72 jC 1min for 40 cycles. Five
microliters of PCR product were run on a 1% agarose gel.
Western blotting
Cells were harvested at the indicated time after trans-
fection, washed with cold PBS, and total proteins were
extracted in the extraction buffer (150 mM NaCl, 50 mM
Tris, pH 7.5, 1% glycerol, and 1% NP-40). Protein
extracts were separated by 10% SDS-PAGE and trans-
ferred to nitrocellulose. Anti-HA antibodies (Roche), anti-
a-tubulin (Santa Cruz Biotechnology) antibodies, and
HRP-conjugated second antibodies (Chemicon) were used
for Western blotting, respectively. Bands were visualized
by ECL reagent and recorded on Image Station 440CF
(Kodak).
Immunostaining
Cells grown on the glass coverslip were fixed by
immersion in 3.7% formaldehyde solution for 30 min at
37 jC. Coverslips were treated in ice-cold methanol/
acetone (3:7 v/v) for 15 min at 4 jC. Air-dried coverslips
were incubated at 37 jC in a humidified atmosphere box,
blocked with 1% BSA in PBS, and then incubated with
primary antibody (1:100 in PBS 1% BSA) for 1 h. After
A. Lu et al. / Virology 324 (2004) 84–89 89three washes with PBS, the coverslips were incubated with
fluorochrome-conjugated second antibody (1:100 in PBS
1% BSA) for 30 min, washed with PBS and mounted with
50% glycerol. Photographs were taken on an Olympus
immunofluorescent microscope (Model BX51TR) and
Apogee Instruments microscopy fluorescence system
(Model KX85).
Virus infection
SARS coronavirus (SARS Cov-p9) was kindly provided
by the Chinese National Institute for Viral Disease Control
and Prevention. The viruses were replicated in Vero-E6 cells
at 35 jC. The cell culture supernatant was harvested 48
h after virus infection and stored at 80 jC for future use.
To test the anti-SARS virus potential of the shRNA expres-
sion plasmids, 1  105 Vero-E6 cells were seeded in a 24-
well plate and transfected with 0.5 Ag shRNA expression
plasmid-A, its mutant plasmid-A* and another negative
control, pSilence1.0-U6, respectively. Twenty-four hours
after transfection, the SARS Cov-p9 viruses in the cell
culture supernatant mentioned above were diluted at 1/
100000 and added to each well. After infection for 45
min at 35 jC, 1 ml modified Eagle’s medium containing
0.8% methylcellulose was added to each well, and the
plaques were visualized by staining with crystal violet 48
h after infection.
Statistical analysis
Statistical analysis was based on t test and performed on
Microsoft Excel. All graphs represent the mean F SD.Acknowledgments
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